B. Metzler Seel. Sohn & Co. Ag Cytokinetics Inc Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Cytokinetics Inc stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 4,698 shares of CYTK stock, worth $229,591. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,698
Previous 4,698
-0.0%
Holding current value
$229,591
Previous $254,000
2.36%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
409Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$717 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$575 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$474 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$380 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$316 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.6B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...